Vendor Intelligence Report: HXNet

Executive summary

Across 156 Finnrick lab tests, HXNet posts 127 pass / 26 fail, an 81% overall pass rate. The record is highly product-specific: GHK-Cu and Tirzepatide sit at the stronger end, while TB-500 and Tesamorelin are weak blind-buy candidates. Ratings also look less comfortable under stricter methodology views, so the practical read is batch verification, not catalog-wide trust.

The public identity trail anchors HXNet to Hebei Xunou New Energy Technology Co., Ltd. on ChemicalBook, not to a separately found HXNet legal entity. The historical hxnet.net storefront is now non-resolving, and the active buying path runs through forum posts, Pastebin warehouse lists, an identified Discord lane, HXTNT/KIRA XUNOU handles, representative names, and an emerging KARA label.

The sharpest operational finding is the reseller split: a public sales-thread operator says orders are routed to HXTNT while some warehouse stock may come from other suppliers. The same record set includes crypto-only payment, limited refund rules, acknowledged underdose and endotoxin incidents, a GHK-Cu fill failure, Tirzepatide endotoxin flags, and Janoshik COA weaknesses involving customer-entered vendor names and report reposting.

That makes HXNet a relative-choice report, not a simple safe/unsafe verdict. The stronger product lines still sit inside an alias-heavy, low-infrastructure operation where the decisive buyer question is whether the exact lot can be tied to a real entity, warehouse, batch, and independently verifiable test.

Inside the full report:

• Per-product Finnrick rates, trajectories, and methodology-divergence charts for all 10 tested products
• ChemicalBook corporate anchor, alias map, and dated event trail across HXNet, HXTNT, KIRA XUNOU, and KARA
• Forum and Pastebin evidence for the reseller transition, warehouse lanes, payment rules, refund policy, and HGH sourcing
• Quality-incident analysis covering endotoxin disclosures, underdose refunds, no-peptide and identity-failure signals
• Janoshik chain-of-custody analysis of client-name handling, customer-submitted reports, and moderator notices
• Infrastructure and reputation exhibits for hxnet.net, NeoPeptideLab, and the Telegram blacklist trail

Risk assessment

• Product-quality risk for TB-500, CJC-1295, and Tesamorelin — high: Finnrick ratings are weak: TB-500 43.84%, CJC-1295 49.17%, and Tesamorelin 50.69%; avoid blind buys without fresh batch-specific testing.
• Product-quality risk for Cagrilintide and BPC-157 — medium: Cagrilintide 66.22% and BPC-157 67.62% materially trail HXNet’s stronger lines, so require batch verification.
• Endotoxin and sterility-risk incidents — high: Vendor/forum records include a second endotoxin-positive batch and Tirzepatide endotoxin flags; injected products require verified sterile handling.
• Underdose / fill-accuracy risk in GHK-Cu and SS-31 incident batches — high: A GHK-Cu 100mg batch tested 22% under and SS-31 was acknowledged with a 25% refund, despite GHK-Cu’s stronger aggregate rating.
• Testing-integrity and COA chain-of-custody risk — high: Janoshik client names can be customer-entered or changed, and the vendor was warned for reposting customer tests, weakening HXTNT-labeled COAs.
• Reseller/sourcing accountability risk — high: kiraHXTNT states they are now a reseller and may use non-HXTNT suppliers for US/EU stock; HGH is disclosed as QSC-resold without retesting.
• Brand-verification and rebrand risk — high: hxnet.net is dead, operations rely on forum/Pastebin/Discord, and KARA/HXTNT/HXNet aliases lack a published official-channel or anti-counterfeit list.
• Review-manipulation / misleading-history risk — medium: NeoPeptideLab shows 'Founded: 2016' despite 2022 incorporation and frozen 148-review/4.7 profile with suspicious username patterns.
• Regulatory/precursor counterparty risk — medium: ChemicalBook materials list PMK/BMK alongside peptide products; no enforcement action is shown, but counterparty exposure is material.